CD318 expression further varied between primary (pAML) and secondary AML (sAML) with a significantly higher expression in the latter (SFI mean 3.3 vs. 5.7; p = 0.025) (Fig. 1e). This evidence concerns the gene CDCP1 and acute myeloid leukemia.